



IRRAS TO PARTICIPATE IN KEY UPCOMING NEUROSURGERY CONFERENCES

- *IRRAflow*[®] system to be demonstrated at both CNS and EANS tradeshows in October

Stockholm, Sweden, October 3, 2018 – IRRAS AB (“IRRAS”), a commercial-stage medical technology company focused on developing and commercializing transformative treatments to manage intracranial fluids, today announced that the company will be participating in the Congress of Neurological Surgeons (CNS) 2018 Annual Meeting from October 6 – 10 in Houston, TX, and the 18th EANS European Congress of Neurosurgery from October 21 – 25 in Brussels, Belgium. These two meetings are key forums for the latest research and technology in the world of neurosurgery, and both attract attendees from all over the world.

"Exhibiting at the CNS and EANS Congresses is an exciting next step in the introduction of *IRRAflow* to the global neurosurgery communities," stated Will Martin, Chief Commercial Officer of IRRAS. "With our recent US 510(k) clearance and eagerly anticipated CE mark re-certification that will then allow us to continue sales in Europe, we are ready to begin the broader launch of our transformational technology at these important events."

The *IRRAflow* system will be on display at CNS in IRRAS' booth 917 and EANS in IRRAS' booth 14. To schedule a hands-on demonstration of the *IRRAflow* system at either event, please contact the company at info@irras.com.

For more information, please contact:

US

Kleanthis G. Xanthopoulos, Ph.D.

President & CEO

+1 800 213 4604

info@irras.com

Europe

Fredrik Alpsten

CFO and Deputy CEO

+46 706 67 31 06

fredrik.alpsten@irras.com

About IRRAS

IRRAS AB (NASDAQ First North Premier: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company's initial product, *IRRAflow*[®], addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. *IRRAflow* received FDA clearance in July 2018.

Regularly during treatment, the *IRRAflow* catheter is automatically flushed to prevent common catheter occlusions from forming. Because *IRRAflow* is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, *IRRAflow* incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco is certified adviser of the company.

The information was released for public disclosure, through the agency of the contact person above, on October 3 , 2018, at 8.30 a.m. (CET).